Free Trial
NASDAQ:SGMT

Sagimet Biosciences (SGMT) Stock Price, News & Analysis

Sagimet Biosciences logo
$8.68 +0.43 (+5.21%)
Closing price 04:00 PM Eastern
Extended Trading
$8.54 -0.14 (-1.62%)
As of 07:57 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Sagimet Biosciences Stock (NASDAQ:SGMT)

Key Stats

Today's Range
$7.93
$8.75
50-Day Range
$3.10
$9.83
52-Week Range
$1.73
$10.43
Volume
813,555 shs
Average Volume
1.08 million shs
Market Capitalization
$266.22 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$26.60
Consensus Rating
Buy

Company Overview

Sagimet Biosciences Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
47th Percentile Overall Score

SGMT MarketRank™: 

Sagimet Biosciences scored higher than 47% of companies evaluated by MarketBeat, and ranked 552nd out of 913 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Sagimet Biosciences has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 5 buy ratings, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Sagimet Biosciences has only been the subject of 1 research reports in the past 90 days.

  • Read more about Sagimet Biosciences' stock forecast and price target.
  • Earnings Growth

    Earnings for Sagimet Biosciences are expected to decrease in the coming year, from ($1.60) to ($4.03) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Sagimet Biosciences is -4.93, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Sagimet Biosciences is -4.93, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Sagimet Biosciences has a P/B Ratio of 1.71. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

  • Read more about Sagimet Biosciences' valuation and earnings.
  • Percentage of Shares Shorted

    16.13% of the float of Sagimet Biosciences has been sold short.
  • Short Interest Ratio / Days to Cover

    Sagimet Biosciences has a short interest ratio ("days to cover") of 2.7, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Sagimet Biosciences has recently increased by 4.10%, indicating that investor sentiment is decreasing.
  • Dividend Yield

    Sagimet Biosciences does not currently pay a dividend.

  • Dividend Growth

    Sagimet Biosciences does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    16.13% of the float of Sagimet Biosciences has been sold short.
  • Short Interest Ratio / Days to Cover

    Sagimet Biosciences has a short interest ratio ("days to cover") of 2.7, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Sagimet Biosciences has recently increased by 4.10%, indicating that investor sentiment is decreasing.
  • News Sentiment

    Sagimet Biosciences has a news sentiment score of 0.51. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 2 news articles for Sagimet Biosciences this week, compared to 2 articles on an average week.
  • Search Interest

    23 people have searched for SGMT on MarketBeat in the last 30 days. This is an increase of 283% compared to the previous 30 days.
  • MarketBeat Follows

    9 people have added Sagimet Biosciences to their MarketBeat watchlist in the last 30 days. This is an increase of 80% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Sagimet Biosciences insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    14.70% of the stock of Sagimet Biosciences is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    87.86% of the stock of Sagimet Biosciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Sagimet Biosciences' insider trading history.
Receive SGMT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Sagimet Biosciences and its competitors with MarketBeat's FREE daily newsletter.

SGMT Stock News Headlines

SGMT Sagimet Biosciences Inc. - Seeking Alpha
Banks aren’t ready for this altcoin—are you?
I've never been more confident about a DeFi opportunity. This isn't about complex trading or risky bets. This is about being in the right place at the right time – and I believe that time is now.
Sagimet Biosciences Inc. (SGMT) - Yahoo Finance
Sagimet Biosciences Inc.
See More Headlines

SGMT Stock Analysis - Frequently Asked Questions

Sagimet Biosciences' stock was trading at $4.50 at the beginning of the year. Since then, SGMT stock has increased by 92.9% and is now trading at $8.68.

Sagimet Biosciences Inc. (NASDAQ:SGMT) announced its quarterly earnings data on Thursday, May, 8th. The company reported ($0.56) earnings per share for the quarter, beating analysts' consensus estimates of ($0.79) by $0.23.

Sagimet Biosciences (SGMT) raised $85 million in an IPO on Friday, July 14th 2023. The company issued 5,312,500 shares at $16.00 per share.

Shares of SGMT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Sagimet Biosciences investors own include XPeng (XPEV), Iovance Biotherapeutics (IOVA), Taiwan Semiconductor Manufacturing (TSM), Avino Silver & Gold Mines (ASM), Tenet Healthcare (THC) and Urogen Pharma (URGN).

Company Calendar

Last Earnings
5/08/2025
Today
7/07/2025
Next Earnings (Estimated)
8/13/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:SGMT
Fax
N/A
Employees
8
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$26.60
High Stock Price Target
$32.00
Low Stock Price Target
$12.00
Potential Upside/Downside
+215.0%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
5 Analysts

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$45.57 million
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$2 million
Price / Cash Flow
N/A
Book Value
$5.08 per share
Price / Book
1.66

Miscellaneous

Free Float
26,166,000
Market Cap
$258.98 million
Optionable
Optionable
Beta
3.35
The 10 Best AI Stocks to Own in 2025 Cover

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

This page (NASDAQ:SGMT) was last updated on 7/7/2025 by MarketBeat.com Staff
From Our Partners